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Introduction
Schistosomiasis is a chronic and debilitating disease which
affects millions of people, particularly the rural poor in
the developing world. Of some 600 million people at risk,
an estimated 200 million are infected, more than half of
which are symptomatic and at least 20 million exhibit
severe disease manifestations (King et al. 2005). Schisto-
somes, the causative agents, are parasitic bloodﬂukes
(Phylum: Platyhelminth; Class: Trematoda) with indi-
rectly transmitted life-cycles involving obligatory alterna-
tion of generations between sexual reproduction in a
mammalian host and asexual reproduction within a mol-
luscan (freshwater snail) host (Fig. 1). The free-living
molluscan intermediate host-infecting larval stages, mira-
cidia, arise from eggs passed in faeces or urine of the
mammalian deﬁnitive host which hatch in freshwater.
Following asexual replication in the intermediate host,
cercariae are released which are infective to the mamma-
lian host, when the hosts come into contact with infected
water. Cercariae actively invade skin, transform to
schistosomula and then migrate through the blood vascu-
lature to the ﬁnal maturation site, the hepatic portal and
mesenteric venous systems for Schistosoma mansoni
(prevalent in sub-Saharan Africa and South America) and
Schistosoma japonicum (prevalent in South-East Asia), and
the blood vessels of the urogenital system for Schistosoma
haematobium (prevalent in sub-Saharan Africa). Of the
three main schistosome species of public health impor-
tance, infection with S. japonicum and S. mansoni is
associated with chronic hepatic and intestinal ﬁbrosis,
whilst S. haematobium infections can lead to ureteric and
bladder ﬁbrosis, calciﬁcation of the urinary tract and
bladder cancer due to the retention of schistosome eggs
within tissues and inﬂammatory response to them
(Vennervald et al. 2000).
Current schistosome control programmes
There is currently no effective vaccine against human
schistosomiasis and interruption of the transmission
cycle through mollusciciding, biological control of the
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Summary
Schistosomiasis is a parasitic disease of signiﬁcant medical and veterinary
importance in many regions of the world. Recent shifts in global health policy
have led towards the implementation of mass chemotherapeutic control pro-
grammes at the national scale in previously ‘neglected’ countries such as those
within sub-Saharan Africa. Evolutionary theory has an important role to play
in the design, application and interpretation of such programmes. Whilst cele-
brating the rapid success achieved to date by such programmes, in terms of
reduced infection prevalence, intensity and associated human morbidity,
evolutionary change in response to drug selection pressure may be predicted
under certain circumstances, particularly in terms of the development of poten-
tial drug resistance, evolutionary changes in parasite virulence, transmission
and host use, and/or competitive interactions with co-infecting pathogens.
Theoretical and empirical data gained to date serve to highlight the importance
of careful monitoring and evaluation of parasites and their hosts whenever and
wherever chemotherapy is applied and where parasite transmission remains.
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ally proved insufﬁcient control methods on their own
(Fenwick and Webster 2006). In areas where schistosomi-
asis is highly endemic therefore, the present goal is to
mitigate the burden of the disease by controlling morbid-
ity (Fenwick and Webster 2006). Chemotherapy with pra-
ziquantel (PZQ) is the mainstay for schistosomiasis
morbidity control, and will remain the drug of choice for
the foreseeable future; the 54th World Health Assembly
recently set a target of treating at least 75% of school-age
children in areas with high schistosomiasis burdens by
2010 (Colley et al. 2001). Linked to this objective, the
Schistosomiasis Control Initiative (SCI), established in
2002 with funding from the Bill & Melinda Gates Foun-
dation, has assisted six sub-Saharan African countries
(Burkina Faso, Mali, Niger, Tanzania including Zanzibar,
Uganda and Zambia) to develop and implement sustain-
able schistosomiasis morbidity control programmes. The
strategy included the donation of PZQ for mass treatment
for schistosomiasis and co-administering, where appropri-
ate, albendazole for soil-transmitted helminthiasis (STH,
caused by the nematodes Ascaris, Trichuris and hook-
worm), combined with the provision of health education.
Over the 5 years of the SCI program to date, more than
43 million treatments have been delivered in the six
countries. Furthermore, the most recent 1.5 million were
treated within an integrated program covering an addi-
tional set of neglected tropical diseases (NTDs) which
include lymphatic ﬁlariasis, onchocerciasis and the bacte-
rial disease trachoma. In all countries the impact of
annual treatments on the prevalence and intensity of
schistosome and STH infection has been impressive (Ko-
ukounari et al. 2007; Zhang et al. 2007). Likewise, a range
of morbidity indicators, such as anaemia, liver, spleen
and bladder pathologies, have all also been signiﬁcantly
reduced as a response to treatment (Koukounari et al.
2006a,b, 2007; Webster et al. 2007a).
The role of evolution in schistosomiasis control
In both the design and evaluation of the success of such
programmes it is very important to consider the parasites
and hosts as active and dynamic forces subject to evolu-
tionary pressures. Evolutionary theory must therefore play
a role both in the monitoring and evaluation, and in pre-
dicting the longer-term impact, of these and future pro-
grammes. The recent shift towards mass antischistosome
chemotherapy may be expected to lead to intensive and
prolonged new selection pressures on the parasites in par-
ticular, leading to a range of genotypic and phenotypic
changes over space and time. The history of the use of
drugs to treat infection shows clearly that in the vast
majority of cases, if the selective pressure exerted by the
drug is sufﬁciently strong at the population level, resistant
strains of the infectious agent evolve and prosper. The
emergence of resistance is almost always (particularly
where resistance is a recessive trait) sigmoid in form over
time, where little evidence for resistance is observed for
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Figure 1 The schistosome life-cycle incorporating some of the potential effects of mass chemotherapy schistosomiasis control programmes on
the different parasite life stages.
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towards a plateau. The magnitude of the plateau depends
on many factors including the intensity of selection and
the relative ﬁtness of wild type and resistant organisms.
The time scale of emergence and gene frequency change
depend on the intensity of the selective pressure and the
generation time of the pathogen, being a few days for
many viruses to many months to years for complex
multi-cellular organisms such as helminths.
Previous studies have shown that, in the laboratory at
least, a range of different speciﬁc selective pressures
imposed on schistosomes can produce rapid changes in
parasite infectivity, fecundity, virulence (here deﬁned as
harm to the host), drug resistance and population genetic
structure within only a few generations (Fallon and
Doenhoff 1994; Davies and Webster 2001; Davies et al.
2001; Webster 2001; Webster and Davies 2001; Webster
et al. 2001, 2003, 2004, 2007b; Gower and Webster 2004,
2005). Such selection pressures may also be predicted to
inﬂuence the dynamics of inter-speciﬁc parasite interac-
tions such as those between different species of schisto-
somes and between schistosomes and other co-infecting
parasites, some of which are also being targeted in these
control programmes (Ernould et al. 1999; Fleming et al.
2006). Parasite evolution can be a key obstacle in the
development of any effective disease control programmes.
Whilst drug resistance is the most obvious example, the
possibility that pathogen life history characteristics, in
particular virulence, but also parasite infectivity, diversity,
population subdivision and transmission strategies, could
also evolve under ﬁeld conditions is beginning to attract
the attention of evolutionary biologists (Ewald 1983;
Woolhouse et al. 2002). Knowledge on how the pheno-
type and genotype of parasite populations may change in
response to such selective pressures may therefore have
important implications for the long-term success of con-
trol programmes.
Impact of mass chemotherapy on schistosome
parasites
Evolution of drug resistance
Anthelmintic resistance is deﬁned as a heritable change in
a population of worms that enables their survival after
chemotherapeutic treatment regimes that have previously
proved to be effective against the same species and
stage(s) of infection. Resistance emerges and establishes as
the selective advantage of the drug resistant phenotype
exceeds that of the wild type at the population level,
which includes within the host and within the host popu-
lation. Both populations are of relevance as a strongly
resistant phenotype will only prosper if it retains an abil-
ity to transmit between hosts. Suboptimal drug concen-
trations, to those deﬁned as optimal in clinical trials, can
pertain as a consequence of the pharmacokinetics and
pharmacodynamics of the drug mediated by host genetic
background, adherence to recommended drug regimens
and other factors such immune-incompetence and nutri-
tional state of the host. Natural selection is the driving
force in all biological systems and with population level
application of drug treatments the risk of parasites evol-
ving various ways to combat the impact of the drug on
survival and reproduction will always exist.
The reliance of human helminth control programmes
on a small number of drugs and the limited investment
in antiparasitic discovery by pharmaceutical companies
makes the control of these diseases highly vulnerable to
the emergence and spread of drug resistance (Fenwick
and Webster 2006). In parasites of veterinary importance,
reports of resistance have been made in every livestock
host and to every anthelmintic class. In some locations
multi-drug resistance has spread to such an extent that it
has jeopardized the small ruminant industry (Prichard
et al. 2007). The public health community must learn
from current problems in the ﬁeld of veterinary medicine
and seek to protect the effectiveness of existing safe and
efﬁcacious human antihelminthic drugs (and the invest-
ment incurred to develop them), particularly as there are
generally few or no alternatives to be expected in the near
future. This may be particularly pertinent for antischisto-
some control, since there is currently only PZQ available
(Fenwick and Webster 2006). Furthermore, there is ample
evidence of the ability of the schistosome parasites to
evolve drug resistant mechanisms under ﬁeld conditions,
as has already become apparent in the case of oxamaniq-
uine, which was in wide use prior to the development
and use of PZQ (Katz et al. 1991; Cioli et al. 1993;
Fallon and Doenhoff 1994; Fallon et al. 1995; Bonesso-
Sabadini and De Souza Dias 2002).
Fortunately, to date, there is no evidence to suggest
that schistosomes have already developed and/or estab-
lished resistance to PZQ under ﬁeld conditions, even
within China despite its widespread use for over 20 years
(Doenhoff et al. 2002; Doenhoff and Pica-Mattoccia
2006). However, clinical investigations carried out, pri-
marily in Egypt and Senegal on S. mansoni (Ismail et al.
1999; Gryseels et al. 2001), the occasional reports of indi-
vidual failures of PZQ in treatment of travellers with
schistosomiasis (Alonso et al. 2006), and the results from
a range of laboratory studies and successful artiﬁcial-
selection of resistance lines, continue to raise concerns
about the existence or development of potential PZQ
resistance in the future (Doenhoff et al. 2002). A further
cause for potential concern is the fact that the mode of
action of PZQ, and the mechanisms and/or genetics of
resistance in laboratory strains, still remains to be eluci-
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role for voltage-gated calcium channels, in particular the
variant b subunit (Greenberg 2007) to PZQ sensitivity,
although other laboratory studies (Valle et al. 2003) sug-
gest that multiple mechanisms of resistance may be possi-
ble. This is an important consideration in predicting and
monitoring the impact of mass control on the evolution
of drug resistance, as such a phenotype could be pre-
dicted to emerge in different populations through varying
mutations which may have different competitive advanta-
ges.
The likelihood and rate of drug resistance emerging is
dependent on the underlying genetics of resistance, the
frequency of resistance genes in the population, the gen-
eration time of the parasite and the strength of selection
pressure imposed. One determinant of the strength of
selection for drug resistance is the proportion of the
population in refugia at the time of treatment. Refugia
provide a pool of susceptible genes that can dilute the
resistant genes in the population, and are now considered
critical in the management of drug resistance in the small
ruminant industry (Van Wyk 2001). For example, high
levels of multi-drug resistance to albendazole, tetramisole
and ivermectin were detected in the nematode parasites
(predominantly Haemonchus contortus and Tricho-
stronglyus spp.) of a goat ﬂock in Eastern Ethiopia but
not in a separately managed sheep ﬂock in the same area,
that had high levels of refugia due to communal grazing
of the sheep with other animals (cattle, goats, camels and
horses). Moreover it was demonstrated that drug resis-
tance in the goat ﬂock could be reversed by introducing
communal grazing with the susceptible sheep population
(Sissay et al. 2006). For human mass chemotherapy treat-
ment of schistosomes such refugia are naturally present,
and could presumably, hypothetically at least, be used in
a similar way if PZQ-resistance was to emerge in human
populations. The sizes of refugia are unknown but are
likely to be high under current treatment schedules. PZQ
is short-acting and generally given only annually (in con-
trast to the, up to, bimonthly frequency commonly used
in animal husbandry) and a signiﬁcant proportion of par-
asites will be in untreated individuals [such as adults or
preschool children (Odogwu et al. 2006)], alternative res-
ervoir host species (see below), the intermediate snail
hosts or as free-living stages. Moreover, immature schis-
tosomes are not susceptible to PZQ action (Go ¨nnert and
Andrews 1977), and thus may also act as refugia. Size of
refugia might, however, be expected to differ between
schistosome species since S. japonicum, for example, is
thought to have multiple domestic and wildlife reservoir
hosts, in contrast to, for example, S. haematobium, which
is essentially a human parasite. Such high levels of refugia
for schistosomes suggests that the likelihood of drug resis-
tance and rate of spread will be low, contrasting markedly
with for example the ﬁlarial nematodes, Onchocerca volvo-
lus (the causative agent of river blindness) and Wuchereria
bancrofti and Brugia malayi (causative agents of lymphatic
ﬁlariasis), where there is some concern of reduced efﬁcacy
of Ivermectin (IVM) in humans in some areas (Osei-
Atweneboana et al. 2007). These parasites are thought to
have low levels of refugia as they have no free-living
stages or reservoir hosts in their life-cycle, and only a
small proportion of the population at any one time being
present in their insect vector.
Another critical component of the strength of selection
for the development of drug resistance will be the ﬁtness
of drug resistant individuals compared to susceptible
individuals in the absence of drug pressure. Studies in
Egypt have shown no increase of drug failure despite
10 years of therapeutic pressure in villages where there
had previously been treatment failures due to the pres-
ence of worms with decreased sensitivity to PZQ (Ismail
et al. 1999; Botros et al. 2005). One possible explanation
as to why and how these resistant worms have not
become a more signiﬁcant portion of the schistosome
population is an inherent ‘cost of resistance’, whereby
resistant genotypes are less ﬁt than their susceptible coun-
terparts in the absence of drug pressure, thereby limiting
their establishment and spread. In all other pathogens
that have been studied intensively under drug pressure,
reduced ﬁtness of the resistant strains in the absence of
drug pressure has been recorded in the early stages of the
emergence of resistance. Subsequently, however, especially
in bacteria, compensatory mutations or genetic changes
occur to increase the ﬁtness of the resistant variants rela-
tive to wildtype (Levin et al. 2000; Orr 2006). Drug resis-
tant parasites may incur costs such as a lower
reproduction rate, especially in the schistosome system
where parasites may be required to co-adapt successfully
to both their intermediate and deﬁnitive hosts. Indeed,
resistant strains have been shown in the laboratory to
exhibit reduced cercarial output and/or increased viru-
lence to their intermediate host compared to susceptible
strains, with some reverting to susceptibility with repeated
lifecycle passage under no treatment (Lamberton 2005).
Mathematical models of selection and evolution have
recently been applied to the issue of the development of
anthelmintic resistance. Such models have identiﬁed, for
instance, those parameters which will be most important
in determining the impact of mass chemotherapy, and
therefore those which should be most closely monitored
when evaluating this impact. The change in frequency of
resistant strains has been predicted to depend on the
interplay between their relative ﬁtness, the degree of selec-
tion pressure exerted by the drug treatments and even the
life-cycle stages on which density dependence operates
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abundance (Feng et al. 2001; Churcher et al. 2006). One
such model has predicted that if parasite reproduction
and virulence are linked to resistance, then drug treat-
ment may lead to the establishment of multiple parasite
strains with many different levels of resistance, though
resistance levels are expected to remain relatively low
when resistance has a cost to the parasites (Feng et al.
2001). Other models have however suggested that, even
with inherent costs of resistance, higher chemotherapeutic
treatment rates, as are now being dispensed within sub-
Saharan Africa, might allow both parasites with lower
drug resistance to successfully invade and co-existence
between susceptible and resistant parasite strains (Xua
et al. 2005). The study of models that meld population
genetics and transmission dynamics is in its infancy.
Much biological complexity is poorly understood (such as
whether the prime resistance gene will be dominant or
recessive) and as such the predictive capability of these
models is limited at present. To improve their predictive
power, more needs to be understood about the mecha-
nisms of resistance and relative ﬁtness properties through-
out the complex life cycles of schistosomes. Our current
ignorance therefore demands that careful monitoring for
the potential evolution of such resistance is part of all
mass chemotherapy based control programmes.
Our ability to detect the emergence of anthelmintic
resistance and to monitor its spread has indeed been
declared as a priority (Prichard et al. 2007). Monitoring
should include in vitro and in vivo drug efﬁcacy assays,
pharmacokinetic analyses and ideally the monitoring of
molecular markers associated with resistance to PZQ
(Southgate et al. 2005). A variety of in vitro and in vivo
assays are available, although whether they are always
good indicators of the susceptibility-resistance status of
parasites has been questioned (Southgate et al. 2005). An
alternative promising method of investigating the possi-
bility of drug resistance in helminth infections of humans
is based on the notion that if rare resistance-conferring
alleles were already present in untreated parasite popula-
tions, their frequency would increase with chemothera-
peutic selection pressure. To test this notion it is
necessary to: (i) identify polymorphic genes that are
undergoing treatment-induced selection; (ii) demonstrate
that the favoured alleles may confer a ﬁtness advantage to
the parasites carrying them in the presence of the drug;
and (iii) link observed (normal and suboptimal) patterns
in response to treatment with parasite phenotype and
genotype before and after repeated treatment. As drug
resistance is a genetic trait, molecular (DNA) markers
perhaps hold the greatest promise for identifying the
development of drug resistance to anthelminthics, and
hence enable further monitoring and subsequent manage-
ment of any spread of such resistance. The early stages of
an effect of treatment would be manifested as a change in
frequency and/or diversity of alleles linked to resistance.
For example, one recent study reported changes in gene
diversity, heterozygosity and in the number of markers
not in Hardy–Weinberg equilibrium in 28 genetic mark-
ers spanning the P-gylcoprotein locus – which is thought
to be linked to ivermectin (IVM) sensitivity – of four O.
volvulus populations from the Volta Region of Ghana.
The authors thereby concluded that the use of IVM for
onchocerciasis control has imposed strong selection on O.
volvulus populations (Ardelli et al. 2006). This conclusion
should not surprise us – it is to be expected in all mass
treatment programmes for all pathogens. However, for
many systems, such as schistosomes and PZQ, molecular
markers linked to potential resistance genes are currently
not available. An international consortium has recently
been formed to develop anthelmintic resistance single
nucleotide polymorphism (SNP) markers for detecting
anthelmintic resistance (Prichard et al. 2007). Such mark-
ers would ideally be mechanistically associated with the
drug resistance phenotype (informative), but could simply
be strongly associated without a mechanistic link (nonin-
formative). Development of such markers will however be
a lengthy progress, particularly given the lack of mecha-
nistic knowledge concerning PZQ action or resistance.
Furthermore the association study design used to identify
informative SNPs requires the existence of two popula-
tions, one that exhibits a particular phenotype and one
that does not, and hence makes such studies difﬁcult in
schistosome populations where drug resistance is not well
characterized. This leaves noninformative markers as an
option to detect the emergence of resistance, although the
large amount of genetic diversity present in schistosome
populations indicates that a very large number of nonin-
formative SNPs would be necessary in order to ﬁnd any
signiﬁcant associations with resistance phenotypes (Roll-
inson et al. 1997).
In the absence of such currently available molecular
markers linked to resistance/susceptibility traits, popula-
tion genetic studies with neutral markers such as micro-
satellites can provide valuable information about
population genetic changes linked to the emergence of
drug resistance. These include whether infections of pre-
viously treated people represent treatment failures (and
therefore putatively ‘resistant parasites’) or new infec-
tions, enabling identiﬁcation of sources of re-infection,
as well as providing important understanding of how
microevolutionary forces, such as migration, gene ﬂow
and genetic drift, might affect the evolution of drug
resistance. Studying movement in parasites and hosts is
important for understanding the evolution of drug
resistance. For example, the widespread occurrence of
Applying evolutionary principles to schistosome control Webster et al.
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result from the recent spread of a few selected alleles,
rather than from the independent evolution of new resis-
tance alleles in multiple locations (Nair et al. 2003;
Roper et al. 2003). Indeed one recent study has reported
that gene diversity in the P-glycoprotein locus in O.
volvolus was reduced even in worms sampled from peo-
ple in neighbouring untreated regions, and suggested
that movements of IVM-treated worms by the ﬂy vector
could be responsible (Ardelli et al. 2006). Such investiga-
tions have recently begun in the schistosome system fol-
lowing the development of microsatellite markers for the
three major species of human schistosomes: S. mansoni
(Durand et al. 2000; Blair et al. 2001), S. japonicum
(Shrivastava et al. 2003) and S. haematobium (Golan
et al. 2007). For example, in an initial study, adult
worms from seven populations of S. mansoni from
Kenya were examined using ﬁve microsatellite markers
with a high level of genetic diversity detected suggesting
that the strong genetic structure observed was a result of
limited gene ﬂow and large population sizes (Agola et al.
2006). An interesting hypothesis to emerge from this
study was that limited gene ﬂow between populations
might hinder the development of drug resistance. Large
scale population genetic studies as part of the monitor-
ing and evaluation of mass human chemotherapy pro-
grammes should investigate a range of factors. These
include the genetic diversity, presence and nature of
population structure and gene ﬂow in human helminth
populations over space and time, estimates of effective
population sizes from allele frequency data and any
changes mediated by mass treatment, in order to deter-
mine the impact of treatment on the parasite population
as a whole. A key problem militating against studies of
schistosomes has, however, been that adult worms can-
not be directly sampled from living hosts, because of
their location deep within the blood vessels surrounding
the intestine and bladder. Traditional indirect sampling
involving passage through laboratory animals in order to
obtain parasite material for analysis presents signiﬁcant
ethical and practical drawbacks, and may result in sam-
pling biases such as bottlenecking processes and/or host-
induced selection pressures. Recent new methodologies
involving advances in room temperature DNA storage
and mutliplexing are allowing direct genotyping of indi-
vidual ﬁeld collected larvae from infected people (Shriv-
astava et al. 2005; Gower et al. 2007). These new
methodologies, which have obvious ethical and biological
advantages, represent an enormous reduction in the
logistical effort required in assaying schistosome popula-
tions. For the ﬁrst time there is now the opportunity to
collect samples from a large number of infected human
individuals at multiple locations.
Evolution of parasite life histories
The evolution of drug resistance is only one dimension
of potential parasite adaptation to human intervention
through mass chemotherapy. Parasite life-history traits,
including a parasite’s survivorship and fecundity within
a host, will evolve in response to selection and their
evolution will be constrained by trade-offs between traits
(Paterson and Barber 2007). Large scale use of chemo-
therapeutic agents against human helminth disease is
likely to result in traits other than those associated with
anthelminthic resistance being under potentially strong
selection – the ultimate prerequisite being heritable vari-
ation on which selection can act. It has been suggested,
for example, that when anthelmintics reduce adult life
expectancy, natural selection will favour parasites that
mature earlier (Medley 1994; Poulin 1998) allowing par-
asites to produce eggs before the host is given anthelm-
inthics but which would result in worms which were
smaller and less fecund. Conversely, Skorping and Read
(1998) argued that parasitic nematodes with larvae in
host tissues (poorly susceptible to treatments) and adults
in the gastrointestinal tract (highly susceptible to treat-
ment) should postpone maturity, become larger and
more fecund. These hypotheses were investigated in Tel-
adorsagia cicumcinta worms infecting sheep, where resis-
tance to one group of antheminthics, the
benzimidazoles, is controlled by a point mutation on
the b-tubulin gene, allowing easy genotyping of worms
into resistant or susceptible categories within individual
isolates over a series of drug treatments (Leignel and
Cabaret 2001). The authors reported that adult worms
became larger when subjected to massive chemotherapy,
in agreement with Skorping and Read’s (1998) hypothe-
sis. Differences in schistosome susceptibility to PZQ has
also been documented and one hypothesis has been a
delayed maturation rate in Senegal (Fallon et al. 1997)
although it is not known if this could be due to previ-
ous PZQ exposure.
Another key component of parasite ﬁtness which has
attracted attention in theoretical studies is the evolution
of parasite-induced harm to the host, or virulence (Bull
1994). Virulence can in some circumstances represents a
cost to parasites, through reducing the duration of infec-
tion and thus transmissibility, and is thus a key source of
selection via its impact on reproductive success. The viru-
lence of parasites is of importance in schistosomiasis con-
trol, as the aim of mass chemotherapy control programs
is the reduction of parasite-induced host morbidity. Drug
treatment with PZQ, in the absence of drug resistance,
will directly reduce parasite infection intensity (i.e. the
numbers of parasites present) but evolutionary changes
in parasite virulence characteristics might affect, either
Webster et al. Applying evolutionary principles to schistosome control
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human morbidity.
A considerable body of theory has been developed to
explain how nonzero levels of virulence can evolve and be
maintained as a result of parasite adaptive evolution
where, for example, increased virulence is concomitant
with increased parasite reproduction despite a reduced
duration of infection. Current theory predicts that though
virulence is costly to the parasite, it may be maintained
or promoted where the ﬁtness costs of being virulent are
offset by beneﬁts such as increased transmission, domi-
nance in intra-host competitive interactions, or the ability
to withstand host defences (May and Anderson 1983;
Frank 1996). Such models most often assume that viru-
lence is a direct side-effect of increased parasite reproduc-
tion, but that such increased reproduction also increases
the probability of transmission to new hosts, or parasite
competitive ability (Bull 1994), resulting in a trade-off
between traits and an ‘optimum’ virulence level that max-
imizes parasite ﬁtness. This has led to ideas of virulence
management (Dieckmann et al. 2002) and speciﬁc predic-
tions about, for instance, public health strategies which
could prompt the evolution of benign parasites (Ewald
1994) or create the conditions which would favour more
virulent pathogens (Gandon et al. 2001). For example,
Porco and colleagues extended the adaptive trade-off
model to consider the effect of chemotherapeutic treat-
ment on such trade-offs (Porco et al. 2005). They consid-
ered that treatment exerts selective pressure by reducing
the duration of an infection, and hence opportunities for
continued reproduction, thereby reducing the value of
duration-increasing strategies to the pathogen and favour-
ing pathogen strategies that maximize the rate of
transmission. Thus when virulence is subject to such a
trade-off, treatment can lead to an increase in optimal
virulence. In other scenarios, however, such as if there is
a trade-off between virulence and host activity levels,
which may determine opportunities for contacts with
other susceptible hosts, they concluded that treatment
decreases the optimal virulence. Theoretical studies based
on parasite adaptive evolution have also proposed multi-
ple or mixed genotype infections as a further mechanism
to promote the maintenance and evolution of virulence
in parasite populations, as intra-host competition can
favour high virulence parasite strains of lower potential
ﬁtness than less virulent strains wherever they have a local
growth or transmission advantage (Anita et al. 1994; May
and Nowak 1994). This is because competition between
strains may select for genotypes that exploit host
resources sooner, regardless of whether they would pro-
duce fewer new infections in the single genotype situation
(Bremermann and Pickering 1983), and may be directly
observed as an increase in the virulence of mixed
infections, or changes in optimal virulence levels over
evolutionary time. Some authors have proposed that
treatment may reduce the incidence of multiple infec-
tions, and thus select for lower virulence [e.g. (Galvani
et al. 2003)]. However, an important point to consider is
that observed virulence will be a product of both parasite
and host factors (Taylor et al. 1998). Host defence against
genetically heterogeneous infections may require more
host resources or such defence may be less effective (Mo-
rand and Harvey 2000; Moret and Schimd-Hempel 2000).
A rise in virulence not necessarily based on parasite adap-
tation, or conversely, parasite diversity itself may be an
important component of the development of adaptive
immunity and hence protection from severe disease.
A feature of schistosome epidemiology is that infection
intensity and disease severity vary considerably between
geographic areas and between individuals within the same
region whether due to age and duration of exposure, host
or parasite genetic background and/or host behaviour.
Laboratory studies, albeit currently limited to S. mansoni,
have demonstrated that such variation can be attributed
in some instances to repeatable differences in parasite
strain (Nelson and Saoud 1968; Kassim et al. 1979;
Chunge et al. 1995; Thiongo et al. 1997) and there is pre-
liminary evidence (from RAPD data) of an association of
speciﬁc parasite genotypes with more intense pathology
in S. haematobium (Brouwer et al. 2003). In the labora-
tory, schistosome traits including infectivity, rates of rep-
lication, transmission and virulence in both the deﬁnitive
and intermediate hosts have been demonstrated not only
to have a genetic basis, but to be sometimes genetically
correlated with rapid responses to artiﬁcial selection
clearly documented (Davies et al. 2001; Gower and Web-
ster 2004; Webster et al. 2004, 2007b). Different, and
sometimes opposing, selective pressures acting on para-
sites within the intermediate and deﬁnitive hosts have
been identiﬁed. These have been postulated to be crucial
to the evolution of pathogens with multi-host lifecycles
(Gandon 2004) and might be expected to promote poly-
morphisms in traits via ﬂuctuating selection, whereby dif-
ferent genotypes, or selection for different alleles, will be
favoured in the different obligatory host stages. Likewise,
infection of hosts by multiple strains of parasite genotypes
has been shown to be associated with exacerbated host
morbidity as a result of intra-host parasite competition
(Davies et al. 2002). However, intra-host competition has
also been documented to favour strains of varying viru-
lence phenotype in this system (Gower and Webster
2005). Thus evolutionary alterations in schistosome life
history characteristics in response to selection imposed by
mass chemotherapy programs may well be likely,
although the direction and strength of selection in ende-
mic ﬁeld situations is unknown. For example, if treatment
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maximize transmission, an increase in egg production and
concomitantly an increase in the morbidity of residual or
untreated infections might be predicted. Conversely, treat-
ment may reduce the incidence of multiple infections,
and hence select for reduced parasite virulence.
In the ﬁeld, and in the absence of genetic markers for
parasite traits such as virulence and fecundity, the impact
of mass chemotherapy on general parasite life-history traits
could potentially be monitored through the integration of
clinical measures and prevalence data with population
genetic analyses using microsatellite markers. Such data
may be valuable in monitoring relationships between prev-
alence, intensity and morbidity measures and associations
of particular genotypes or degrees of genetic diversity in
clinical phenotypes (such as population subdivision
between areas or individuals with differing morbidity or
infection intensity, which would suggest that parasite strain
variability may be a potential contributing factor) and the
effect of chemotherapeutic treatment on such associations.
However, detecting alterations of parasite reproductive
strategies is particularly difﬁcult in schistosomes, as adult
worm burdens cannot be assessed in living hosts, although
population genetic studies may give some indications of
changes having occurred. For example, a reduction in the
genetic diversity of infections of similar intensity might be
evidence of decreases in per capita egg production.
All organisms, including parasites, have limited
resources that can be allocated to various functions such
as growth, survival and reproduction. Maximizing ﬁtness
(lifetime reproductive success) may involve trade-offs
between such traits. Strategies of resource allocation that
maximize ﬁtness can differ between benign and stressful
environments, including that of stresses imposed by che-
motherapy (Buckling et al. 1997). Consequently natural
selection often favours phenotypic alteration of reproduc-
tive effort in response to stress. For example, increased
reproductive effort, termed fecundity compensation,
should follow cues associated with a decreased probability
of future survival or reproduction – this has been
observed in the enhanced egg production occurring in
infected crickets (Adamo 1999), infected Daphnia (Chad-
wick and Little 2005) and snails that have been exposed
to castrating parasites (Minchella and LoVerde 1981; Blair
and Webster 2006). Secondly, if conditions change such
that one life history stage becomes relatively more vulner-
able than another, increased investment into the least vul-
nerable stage is predicted [the ‘safe harbour’ hypothesis
(Shine 1978)] Similar parasite life history counter-adapta-
tions may be associated with the stresses imposed by
human intervention strategies such as chemotherapy.
For example, a subcurative dose of the antimalarial
chloroquine has been demonstrated to cause malaria par-
asites to divert resources from within host asexual replica-
tion to the production of transmission stages
(gametocytes) in a Plasmodium chabaudi laboratory
model (Buckling et al. 1997). These alterations lead to
correlated changes in infectivity to mosquitoes, with the
consequence that chloroquine treatment had no effect on
the proportion of mosquitoes infected. Whilst such phe-
notypic plasticity may be less common in more complex
multicellular organisms such as the helminth parasites,
recent experimental studies of the ﬁsh trematode, Coito-
caecum parvum, have suggested that they too can use
information about transmission opportunities to trigger
life history alterations. In this example accelerated devel-
opment and precocious maturity of larvae in intermediate
hosts was observed in the absence of either chemical cues
emanating from the ﬁsh deﬁnitive host or the presence of
high intermediate host mortality (Poulin 2003). Recent
laboratory studies of S. mansoni have also shown that
when intermediate hosts are stressed due, for example, to
starvation, the resulting reduced parasite success in that
intermediate host stage appears to be subsequently
traded-off with increased parasite investment and subse-
quent success within the deﬁnitive host stage
(C. M. Gower, L. Blair and J. P. Webster, unpublished
data). Such studies further indicate that there may be
phenotypic plasticity in this system that may aid mainte-
nance of transmission in response to stress. If such mech-
anisms do exist, it might be predicted that human
treatment would promote an increase in the reproductive
importance of the snail component of the life history,
and therefore, that the force of transmission may not be
reduced as much as expected by reference to reductions
in the intensity and prevalence of human infections. This
further underlines the importance of morbidity reduction
as the major goal of current schistosomiasis control
programmes.
Impact of mass chemotherapy on interactions
between different species of schistosome and
between schistosomes and other parasites
In the developing world co-infections and polyparasitism
within humans appear to be the rule rather than the
exception. For example, co-infections between S. mansoni
and S. haematobium have been reported in an increasing
number of foci in sub-Saharan Africa (Cunin et al. 2000,
2003a; Garba et al. 2004) and also with species of STHs
(Brooker et al. 2000; Tcheum Tchuente et al. 2003; Flem-
ing et al. 2006). Inter-speciﬁc interactions between para-
sites are expected to occur when there are co-infections.
One of the main characteristics of these interactions
relates to whether they result in a positive or negative
association between the abundances of different parasite
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interactions, where infection of a host by one parasite
species enables infection of that host by a second parasite
species which would otherwise not be able to infect. Neg-
ative interactions occur due to inter-speciﬁc competition:
the competition between two species of parasites
co-infecting a host for limited niches and/or resources.
Both types of interaction may be mediated by the host
immune system through either suppression of
the immune response allowing facilitation or stimulation
of a immune response in the case of competition (Schad
1996). Such synergistic or antagonistic interactions of
co-infections may clinically affect individuals and
co-endemicity may affect the epidemiology of the
parasites (Keusch and Migasena 1982). Polyparasitism
may also be likely to have a large impact on both the
parasites and the host involved as it may affect parasite
growth, maturation, reproductive success and survival
along with the susceptibility, morbidity and immune
response of the host (Keusch and Migasena 1982).
The effects of interactions between S. haematobium and
S. mansoni on parasite dynamics were originally investi-
gated in the ﬁeld, where studies in Cameroon and Senegal
revealed that in areas of overlap S. mansoni eggs were
being excreted in urine samples of humans as opposed to
the usual faecal route (Ratard et al. 1991). This indicated
that male S. haematobium worms and female S. mansoni
worms (which cannot successfully hybridize) were pairing
heterospeciﬁcally and migrating to the urinary oviposition
site, resulting in S. mansoni-shaped eggs in the urine
(through parthenogenesis). Laboratory studies revealed
that S. haematobium males compete with, and are more
successful than, S. mansoni males in pairing with S. man-
soni females (Webster et al. 1999). When such competi-
tion exists in a system there is the risk of exclusion, either
partially or totally, of one species by another and such
mating competition has been implicated in limiting the
distribution of another less common schistosome species,
S. intercalatum, due to competitive interactions with
S. mansoni (Tchuem Tchuente et al. 1995). However, the
outcome of such competition is difﬁcult to predict as it
relies on several factors relating to the individual parasite-
life histories. These include the relative infectivity of the
parasites, length of life-cycle (shorter for S. mansoni), sex
ratio (more female biased for S. mansoni) and male com-
petitive pairing ability (greater for S. haematobium).
Indeed dominance in mating competition may in some
cases result in a reduction in fecundity for the dominant
species due to the fact that hybridization does not occur
(Webster et al. 1999). In areas of overlap between S. man-
soni and S. haematobium in Egypt, for example, S. man-
soni has been observed to be replacing S. haematobium
and at least in this focus S. mansoni appears to be
competitively dominant (Adel-Wahab et al. 1993). How-
ever, interactions between schistosomes and co-infecting
STHs have not been so extensively studied. In many
reports of the levels of co-occurrence for these two
groups of parasites in the same individuals it appears that
the parasites may be positively associated with each other
and therefore undergoing positive inter-speciﬁc interac-
tions such as facilitation of infection of one species by the
other or synergistic effects on the host immune response
once co-infected (Tcheum Tchuente et al. 2003; Fleming
et al. 2006). Competitive interactions have, however, been
identiﬁed despite this, through for example the observa-
tion of reduced infection intensities for Ascaris lumbrico-
ides and S. mansoni in co-infections in comparison to
individual infections (Fleming et al. 2006). In all such
work based on ﬁeld observations, care must be taken,
nevertheless, in the interpretations of simple correlations
between the abundances of different parasite species
within hosts. Many factors other than competition or
facilitation could inﬂuence such patterns, including the
nutritional state or immunocompetence of the host, host
behaviour and the environment of the host population.
Mass chemotherapy may be predicted to impact on
such complex dynamic interspeciﬁc interactions, espe-
cially if the selection pressure differs between the parasite
species. For example effects will be observed if PZQ efﬁ-
cacy is different for S. mansoni and S. haematobium or if
the efﬁcacy of PZQ on schistosome infections is different
to that of albendazole for STHs. Indeed, as regards the
former, whilst PZQ works on all species of schistosome
infecting humans,, there is some evidence of differential
susceptibility, where potential tolerance (or even
resistance) to S. mansoni has been detected but not for
S. haematobium (Southgate et al. 2005). Moreover, as
S. mansoni and S. haematobium differ in the generation
times/length of time to maturation, and as juveniles
schistosomes are not susceptible to PZQ, this too could
potentially lead to differences between these two species.
Such differences could affect the order of establishment of
the parasites within their human hosts [a factor known to
be very important in determining the outcome of inter-
speciﬁc competition (Cosgrove and Southgate 2002)].
Also, if for example, PZQ resistance was to develop in
one schistosome species (say S. mansoni) it could not be
passed between the species (due to their inability to
hybridize). One could hypothesize that in conditions of
high drug imposed selection this could lead to S. mansoni
having increased competitive dominance over S. haemato-
bium in areas of overlap. However in conditions of
reduced drug imposed selection (possibly due to the iden-
tiﬁcation of such drug resistance in the S. mansoni spe-
cies), S. haematobium could be competitively dominant
due to inherent costs in S. mansoni’s drug resistance.
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tion to drug resistance emerging for either schistosomes
or STHs. Such theories, although somewhat speculative at
this stage, highlight the importance of monitoring and
evaluating the impact of mass chemotherapy control pro-
grammes on such inter-speciﬁc interactions. Limited evi-
dence is just emerging of possible competitive
interactions. For example, one study found an increase of
intestinal schistosomiasis after PZQ treatment in a S. hae-
matobium and S. mansoni mixed focus in Senegal (Ern-
ould et al. 1999). In one village, where the two parasites
were present before treatment, the disappearance of the
urinary schistosomiasis after treatment was concomitant
with a dramatic increase of intestinal schistosomiasis:
S. mansoni egg excretion was seven times higher than
before treatment. The direct cause of this change is
unknown. However possible reasons include lack of activ-
ity of PZQ against S. mansoni in this focus, a reduction
in mating competition, within which S. haematobium is
dominant (Webster et al. 1999), and/or the fact that it
was a developing (epidemic) focus.
Inter-speciﬁc interactions may also be predicted to
directly impact morbidity, as well as affecting the preva-
lence and intensity of human infections. For example,
positive associations between mixed infections of different
species of schistosomes and of schistosomes and STHs,
and increases in parasite infection intensity have been
observed (Brooker et al. 2000; Tcheum Tchuente et al.
2003; Fleming et al. 2006). However, associated increases
in morbidity have not yet been determined. One study on
interactions between S. mansoni and S. haematobium has
identiﬁed a potential effect of inter-speciﬁc interactions
on host morbidity. This study did not support the specu-
lative evolutionary theory which predicts that more
diverse infections are more costly to the host (Anita et al.
1994; Bonhoeffer and Nowak 1994; Nowak and May
1994; van Baalen and Sabelis 1995; May and Nowak 1995;
Frank 1996). Instead it reported a lowering of S. mansoni
induced morbidity (hepatomegaly and splenomagaly mor-
bidity) in mixed infections with S. haematobium relative
to that observed for S. mansoni single infections (Cunin
et al. 2003b). The authors suggest that this lowering effect
on liver morbidity could be due to S. haematobium males
mating with S. mansoni females with the eggs from such
couplings passing to the urinary tract (the S. mansoni
females will lay parthenogenic eggs shaped like normal
S. mansoni eggs and the S. haematobium male will carry
the female to the normal S. haematobium egg-laying site,
i.e. the urinary tract, resulting in S. mansoni-shaped eggs
in urine), thereby reducing the amount of classical
S. mansoni induced morbidity. The consequence of typical
S. haematobium-associated bladder pathology was not,
however, investigated in this preliminary study on mixed
species infections, and further work to evaluate this is
underway (Gouvras et al. in press). The effects of chemo-
therapeutic treatment on such inter-speciﬁc interactions
between parasites generally may well be predicted to have
implications for the morbidity induced by such mixed
infections on human hosts, due to a general lowering
effect of treatment on infection prevalences of each, or
one or other, of the separate parasites species.
Co-evolutionary interactions between schisto-
somes and their molluscan intermediate host
Mass chemotherapy programs might also be likely to
affect co-evolutionary interactions between helminths
and their hosts, particularly in those with part of the
lifecycle in short-lived intermediate hosts, whose genera-
tion times are roughly similar to those of their infecting
parasites, such as schistosomes and their freshwater snail
hosts. Snail-trematode compatibility is a highly speciﬁc
relationship, often at the population or strain levels for
both participants (Lo and Lee 1995; Webster and Wool-
house 1998; Webster 2001; Webster and Davies 2001).
This speciﬁcity has the important practical effect of lim-
iting medically important trematodes such as schisto-
somes to geographic areas occupied by compatible snails
(van der Knapp and Loker 1990). Studies have demon-
strated both that snail resistance to schistosome infection
is a heritable genetic trait (Lo and Lee 1995; Webster
and Woolhouse 1998; Webster 2001; Webster and Davies
2001) and that schistosome infection presents a signiﬁ-
cant ﬁtness cost to host snails in terms of increased
mortality and reduced fertility (Woolhouse 1989; Web-
ster and Woolhouse 1999). However, natural host popu-
lations often exhibit considerable genetic variability in
resistance to parasitism. Co-evolutionary theory suggests
that one potential mechanism for maintaining such
diversity is a trade-off between ﬁtness costs associated
with resistance and ﬁtness costs associated with parasit-
ism (May and Anderson 1983; Fritz and Simms 1992;
Frank 1994). Examples of such as a cost of resistance in
snails to their schistosomes, in terms of reduced egg fer-
tility but not necessarily fecundity, have been demons-
trated (Webster and Woolhouse 1999). Selection for
susceptible snails, mediated by the high costs of resis-
tance, also has wider implications for schistosomiasis
control measures. Most importantly, if a reduction in
net transmission rates due to mass chemotherapy favours
an increase in the susceptibility of the snail population,
then this may increase the likelihood of the re-emergence
of the disease should control measures be relaxed. This
could serve to reinforce any increased susceptibility of
the human population due to loss of, or a reduction in,
acquired immunity.
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The potential impacts of mass chemotherapy pro-
grammes on parasites and intermediate hosts are also
important in relation to their overall effect on infection
intensity and virulence of schistosomes within their
human host. Mass chemotherapy control programmes
may, however, also be predicted to impact on human
hosts directly. It is now widely accepted that humans
exhibit an acquired immunity to schistosome infections
which develops slowly as individuals’ age and accumu-
late exposure experiences. In schistosome endemic areas,
human infection levels typically increase during child-
hood, peak during adolescence and decline during
adulthood (Gryseels et al. 1995; Mutapi et al. 2006), a
pattern which is in part attributed to cumulative expo-
sure to infection and the development of gradually
acquired resistance to schistosomes, and in part due to
behavioural changes with age that are related to expo-
sure to infection. Some parasite antigens that are
thought to play some part in stimulating such protective
acquired immunity are located beneath the worm tegu-
ment of adult schistosomes and are therefore only avail-
able to the immune systems when the tegument is
damaged or worms die (Mutapi 2001). Adult schisto-
some worms are known to live for, on average, between
3 and 7 years. If these antigens beneath the worm tegu-
ment are the key stimulants of acquired immunity, this
observation on life expectancy may be linked with the
fact that it takes several years for infected children to
‘acquire’ resistance (Mutapi 2001). The potential effects
of mass chemotherapy on host acquired resistance have
been extensively studied. Mass chemotherapy control
programmes may be predicted to prevent the develop-
ment of naturally acquired resistance to infection, and
may therefore have detrimental effects, at least in terms
of the proportion of humans infected, if control ceases
and individuals continued to be highly infected at older
ages without having developed any acquired immunity
during childhood. Similar concerns apply for the control
of many parasitic infections such as the malarial para-
sites. However, studies to date indicate that the expo-
sure of the host immune system to parasite antigens
through the damage and subsequent killing of adult
schistosome worms by the action of PZQ actually stim-
ulates a form of acquired immunity itself. This ‘chemo-
therapy-induced’ acquired immunity has been shown to
be different to naturally acquired immunity (Correa-
Oliveira et al. 2000; van den Biggelaar et al. 2002), pos-
sibly due to differences between the large amounts of
antigens from adult worms released over a small time
period directly into the host bloodstream due to PZQ
action. In contrast, in the absence of treatment smaller
amounts of various antigens are released over a long
period of time through the skin, lungs, liver and the
blood from adult and juvenile worms (Mutapi 2001).
There is ongoing debate as to the effectiveness of such
treatment-acquired-immunity in comparison to naturally
acquired immunity in relation to the amount and dura-
tion of protection that it provides (van den Biggelaar
et al. 2002). Nevertheless, it may well be of value to
monitor the effectiveness of such treatment-acquired
immunity in relation to mass chemotherapy control
programmes over space and time. One way to do this
may be to measure reinfection rates by age group, dis-
counting for the herd impact of mass treatment, to see
if this drug induced immunity reduces establishment of
the adult worms.
Mass chemotherapy schistosomiasis control pro-
grammes do not only involve the administration of che-
motherapy, but also the provision of health education.
Health education may be predicted to have a large
effect on humans if it achieves its aim of changing
human water-contact behaviour. Two facets of human
water-contact behaviour are important; human defeca-
tion and urination into water containing schistosome
intermediate host snails and human contact with water
containing infective schistosome cercariae. Changes in
these two facets of water contact are likely to have dif-
ferent relative effects in terms of human exposure to
schistosomes, as well as broader aspects of the transmis-
sion dynamics of schistosome populations. A complete
cessation in contact with water containing cercariae
would prevent human schistosome infection. However,
considering the current infrastructure in communities
with endemic schistosomiasis this is not a likely out-
come of such control programmes. Instead some degree
of reduction in both of these types of water contact is
possible and they would be expected to reduce preva-
lence and infection intensity for human hosts in general,
and thereby also potentially impact the selective pres-
sures imposed upon parasite virulence and/or other life
history traits.
Impact of mass chemotherapy relating to
nonhuman deﬁnitive hosts
Although mass chemotherapy programmes are speciﬁcally
directed at reducing human morbidity, they may have
implications for other deﬁnitive hosts of schistosomes.
For example, mass chemotherapy may be important both
in terms of their effects on these hosts (which may
potentially be important livestock) but also for their role
previously discussed as refugia and also as reservoirs for
re-infection of human hosts. The number of nonhuman
deﬁnitive hosts vary greatly between the schistosome
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human parasite, S. mansoni infecting humans, rodents
and primates (Morand et al. 1996; Muller-Graf et al.
1997) and S. japonicum infecting humans and a very wide
range of nonhuman hosts (Wang et al. 2006). The impor-
tance of nonhuman hosts as both sources of reinfection,
and conversely as refugia, will depend on whether the
parasite population is panmitic or whether parasite strains
are present which are circulating independently within
hosts of different types. For example, cross-infections
have been demonstrated to be rare between Ascaris nema-
todes of humans and pigs in sympatric areas (Anderson
and Jaenike 1997). Thus, although infections of humans
are unlikely to occur from pig-derived parasite popula-
tions, these populations won’t act as natural refugia either
unless at some point they come into contact with
human–derived worms. Wang and colleagues also used
microsatellite markers to examine S. japonicum across a
range of host species in China and reported that parasites
were circulating between humans and all the domestic
animals species studied, although with some strain struc-
ture present and greatest potential transfer between
humans and bovines, at least within the marshland
regions (Wang et al. 2006).
Mass chemotherapy treatment may be predicted to
impact on the infection of nonhuman deﬁnitive hosts as
any ‘human adapted strains’ would be killed via PZQ
treatment in humans giving any ‘nonhuman host’
adapted strains a distinct competitive advantage. It is
likely therefore, that there will be strong selective pres-
sure for further adaptation of schistosomes to their non-
human hosts which may have detrimental effects for
these hosts. Conversely for human hosts different scenar-
ios may be predicted relating to the extent to which
schistosomes adapt to transmission in these nonhuman
hosts. If PZQ treatment in human hosts imposes a very
strong selection pressure on parasites to adapt to their
nonhuman hosts, then schistosomes may adapt to solely
infect these nonhuman hosts. Indeed there appears to be
clear evidence of this already happening in response to
differing environmental selective pressures being imposed
on schistosomes in Guadeloupe, with the recent adapta-
tion of S. mansoni (back) to its rodent host (Theron
1984; Theron et al. 1992) and an associated potential
decrease in risk of further human infection. With inter-
mediate levels of selection pressure imposed by PZQ
treatment it may conversely be predicted that schisto-
some infections within nonhuman hosts may act as
reservoirs for human re-infection. Indeed there are data
to suggest this may already be occurring within both
S. mansoni (Muller-Graf et al. 1997) and S. japonicum
(D. Lu, J. Rudge, T. Wang and J. P.Webster, unpub-
lished data).
Conclusions and recommendations
Recently implemented mass-chemotherapeutic control
programmes have been shown to have a rapid and dra-
matic impact on reducing schistosome prevalence, inten-
sity and subsequent human host morbidity. However, as
control efforts gather pace across sub-Saharan Africa the
wider availability of PZQ may exacerbate the risk of the
emergence of drug-resistant parasites. This provides a
strong incentive to extend monitoring and surveillance
and to increase investigation of the population biology
and genetics of potentially resistant parasites and the ﬁne
detail of resistance mechanisms. Unfortunately to date
there are very limited empirical data available relating to
any natural genetic diversity in schistosome, or indeed
any helminth, populations or how any of the variations
observed in the few published studies inﬂuence the biol-
ogy of the parasite and its clinical impact on humans or
animals. This situation for helminths is in marked
contrast to that pertaining for most other important
pathogens of humans – especially the viruses and bacteria
– where large international databases exist recording
sequence variation in isolates from different clinical and
epidemiological settings. Given the growth in interest in
the community based control of helminth infections by
chemotherapy, much greater attention needs to be direc-
ted towards recording genetic diversity in a systematic
manner in databases that also reﬂect epidemiological and
treatment experience. Records of sequence variation need
to take account of the fact that over the last 40 years
schistosome research has been over-dependent on labora-
tory-reared parasites repeatedly passaged through a
variety of mouse strains, which we know may not repre-
sent the ﬁeld population (Shrivastava et al. 2005; Gower
et al. 2007).
Evolutionary theory has a role in the design, applica-
tion and interpretation of such programmes. It is perhaps
most important here in terms of identifying where change
may occur in the host parasite system as a result of PZQ
treatment and therefore allowing us to design effective
monitoring processes to identify if and in which direction
these changes actually occur (Table 1). Whilst there may
well be currently limited evidence (and/or studies per-
formed to look for it) that evolutionary changes in natu-
ral schistosome or host populations have occurred as a
result of current PZQ control efforts, it is axiomatic that
such changes are expected under the intensity of selection
created by community based control interventions. How-
ever, their relative importance to the success of control
programmes will be determined by the speed of parasite
adaptive evolution, and the genetic variation present
upon which selection may act, which may itself be
reduced by mass chemotherapy treatment. In foci where
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sufﬁciently rapidly to undergo substantial life history
adaptation before elimination. However, it must be con-
sidered, that the major focus of current schistosomiasis
control programs is morbidity, rather than transmission
control, and thus evolutionary considerations are greater
in this context than perhaps in control programs attempt-
ing parasite eradication. The imperative to control these
debilitating infections using the best tool available (i.e.
chemotherapy) is obvious. However, we do suggest that
consideration of control measures from an evolutionary
standpoint is of importance given the history of the
impact of wide scale chemotherapeutics on the evolution
of resistance across a very wide range of organisms. Con-
tinued monitoring and evaluation of parasites and their
hosts whenever and wherever transmission remains must
become an essential arm of intervention. For schisto-
somes, concerns over the evolution and rapid spread of
resistance are somewhat less than for most pathogens for
reasons explained in this review but especially the large
predicted refugia and ﬁtness costs involved. Nevertheless,
it must not be forgotten that schistosomes have already
evolved resistance to oxamniquine (Katz et al. 1991; Cioli
et al. 1993; Fallon and Doenhoff 1994; Fallon et al. 1995;
Bonesso-Sabadini and De Souza Dias 2002). Schistosome
control programmes such as that of the SCI in sub-Saha-
ran Africa have, wherever logistically and ﬁnancially feasi-
ble, already integrated such detailed evolutionary/
resistance monitoring and evaluation of host and parasite
factors. In addition to the parasite prevalence, intensity
and subsequent parasite-induced morbidity levels closely
monitored in each population, SCI monitors the genotype
and phenotype of the parasite at baseline, prior to the
new chemotherapeutic intervention, and then, both in the
population overall, but speciﬁcally in identiﬁable age-
structure longitudinal cohorts of children over space, time
and treatment history, to observe the effect on epidemio-
logical patterns and parasite genetic diversity.
It is unethical to withhold treatment for individuals in
order to obtain ‘control’ data of parasites over space and
time within such mass control programmes. However, by
examining the parasites, either repeatedly within countries
prior to mass drug implementation, and the cercariae
released from the sympatric snail intermediate host popu-
lations, and in conjunction with the miracidia released
from the new 6–7-year-old child recruits at each site and
over each year, it is possible to elucidate the potential
impact on the parasite populations. Much still remains to
be achieved, and indeed the requirement of novel molec-
ular markers for PZQ-resistance are central to an
improved understanding. We recommend that where at
all possible all future large scale human and indeed ani-
mal helminthiasis-control programmes initiate detailed
monitoring and evaluation of host and parasite genetic
diversity factors from their onset. In making this recom-
mendation we fully recognize the cost implications but
the trend in sequencing costs at least give optimism that
this type of monitoring can be without detriment to the
resources directed at morbidity control.
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